RESUMEN
BACKGROUND: Coronary-artery-disease (CAD) is the leading cause of death worldwide, and hence there is a need to identify reliable markers for identifying individuals at high risk of developing CAD. Interleukin-10 (IL-10) is an anti-inflammatory cytokine that is associated with an increased risk of developing both atherosclerosis and acute coronary events. The study aimed to explore the association of a genetic variant in IL-10 with the risk of developing CAD and the severity of the disease. To further explore, a systematic review and meta-analysis was performed. The cumulative results of the relationship between IL and 10 -592 C > A polymorphism and CAD in Iranian population have also been presented. METHODS: In this cross sectional study, a total of 948 individuals including 307 healthy controls and 641 patients that among cases, four hundred and fifty-five of the patients had > 50% stenosis (angiogram positive group) and 186 patients had < 50% stenosis (angiogram negative group) were recruited from the Mashhad-Stroke and Heart-Atherosclerotic-Disorders cohort. Genotyping for the IL-10 -592 C > A polymorphism was performed using a PCR-RFLP technique, and statistical analysis undertaken by univariate and multivariate analyses. PubMed, Google Scholar and Scopus were searched for papers related to this polymorphism up to October 2019. The Meta-analysiswas done based on the random effect model using a Meta-analysis. RESULTS: In our study, the frequency of the variant A allele of the IL-10 -592 C > A was significantly higher in CAD patients than the control group (P value = 0.043). Moreover, subjects carrying AA genotype had a significantly higher risk of CAD (OR: 1.8, 95%CI: 1.04-3.16), p = 0.03), compared to those with the wild type genotype. The results of meta-analysis of 9336 cases and 8461 controls did not also show any significant association between IL and 10 -592 C > A and CAD in dominant and recessive genetic models but only in co-dominant model when fix effect was applied. CONCLUSION: Although our research findings support a significant association of genetic polymorphism in the IL10 gene with cardiovascular diseases, this finding cannot be confirmed in meta-analysis. Further functional analysis and evaluation of this marker in a multicenter setting are needed to establish its value as a risk stratification marker.
Asunto(s)
Enfermedad de la Arteria Coronaria/genética , Predisposición Genética a la Enfermedad/genética , Interleucina-10/genética , Polimorfismo de Nucleótido Simple/genética , Alelos , Aterosclerosis/genética , Estudios de Casos y Controles , Estudios Transversales , Femenino , Genotipo , Humanos , Irán , Masculino , Persona de Mediana Edad , Polimorfismo de Longitud del Fragmento de Restricción/genéticaRESUMEN
BACKGROUND/AIMS: The C1431T polymorphism of peroxisome proliferator activated receptor-γ (PPAR-γ) gene is related to diabetes and metabolic-syndrome. However, studies have been inconclusive about its association with coronary artery disease (CAD) and there have been no studies analyzing the association of this polymorphism with fasted-serum-lipid levels in Iranian-individuals with CAD. We investigated the association of PPAR-γ C1431T-polymorphism with CAD and dyslipidaemia in 787 individuals. METHODS: Anthropometric-parameters and biochemical-measurements were evaluated, followed by genotyping. The association of the genetic-polymorphisms with CAD and lipid-profile was determined by univariate/multivariate-analyses. RESULTS: Patients with CT or CT+TT genotype were at an increased-risk of CAD relative to CC-carriers (adjusted odds ratio: 2.03; 95% confidence interval, 1.01-4.09; p = 0.046). However, in the larger population, CT genotype was present at a higher frequency in the group with a positive angiogram. Furthermore, CT+TT genotypes were associated with an altered fasted-lipid-profile in the initial population sample of patients with a positive angiogram, compared to the group with a negative-angiogram. The angiogram-positive patients carrying the T allele had a significantly higher triglyceride, serum C-reactive protein and fasting-blood-glucose. CONCLUSION: We have found the PPAR-γ C1431T polymorphism was significantly associated with fasted serum lipid profile in individuals with angiographically defined CAD. Since accumulating data support the role of PPAR-γ polymorphisms in CAD, further studies are required to investigate the association of this polymorphism with coronary artery disease.
Asunto(s)
Enfermedad Coronaria/sangre , Enfermedad Coronaria/genética , Lípidos/sangre , PPAR gamma/genética , Polimorfismo Genético , Adulto , Estudios Transversales , Ayuno , Femenino , Predisposición Genética a la Enfermedad , Genotipo , Humanos , Masculino , Persona de Mediana Edad , Oportunidad RelativaRESUMEN
BACKGROUND: A total of 30-40% of diffuse large B cell lymphoma (DLBCL) patients will either not respond to the standard therapy or their disease will recur. The first-line treatment for DLBCL is rituximab and combination chemotherapy. This treatment involves the chemotherapy-induced recruitment of tumor-associated macrophages that recognize and kill rituximab-opsonized DLBCL cells. However, we lack insights into the factors responsible for the recruitment and functionality of macrophages in DLBCL tumors. METHODS: We have studied the effects of the immunomodulatory lipid sphingosine-1-phosphate (S1P) on macrophage activity in DLBCL, both in vitro and in animal models. RESULTS: We show that tumor-derived S1P mediates the chemoattraction of both monocytes and macrophages in vitro and in animal models, an effect that is dependent upon the S1P receptor S1PR1. However, S1P inhibited M1 macrophage-mediated phagocytosis of DLBCL tumor cells opsonized with the CD20 monoclonal antibodies rituximab and ofatumumab, an effect that could be reversed by an S1PR1 inhibitor. CONCLUSIONS: Our data show that S1P signaling can modulate macrophage recruitment and tumor cell killing by anti-CD20 monoclonal antibodies in DLBCL. The administration of S1PR1 inhibitors could enhance the phagocytosis of tumor cells and improve outcomes for patients.
RESUMEN
In this study, we have re-evaluated how EBV status influences clinical outcome. To accomplish this, we performed a literature review of all studies that have reported the effect of EBV status on patient outcome and also explored the effect of EBV positivity on outcome in a clinical trial of children with cHL from the UK. Our literature review revealed that almost all studies of older adults/elderly patients have reported an adverse effect of an EBV-positive status on outcome. In younger adults with cHL, EBV-positive status was either associated with a moderate beneficial effect or no effect, and the results in children and adolescents were conflicting. Our own analysis of a series of 166 children with cHL revealed no difference in overall survival between EBV-positive and EBV-negative groups (p = 0.942, log rank test). However, EBV-positive subjects had significantly longer event-free survival (p = 0.0026). Positive latent membrane protein 1 (LMP1) status was associated with a significantly lower risk of treatment failure in a Cox regression model (HR = 0.21, p = 0.005). In models that controlled for age, gender, and stage, EBV status had a similar effect size and statistical significance. This study highlights the age-related impact of EBV status on outcome in cHL patients and suggests different pathogenic effects of EBV at different stages of life.
RESUMEN
Selective delivery of drugs to damaged tissues favorable to reduce the side effects while enhancing the therapeutic efficacy. The purpose of the present study was the design and synthesis of multi-targeted nanoparticles for co-delivery of both drug and nucleic acid to cancer cells. In this study biocompatible compounds such as chitosan, polyethylene glycol (PEG), polycaprolactone (PCL), folic acid (FA) and glucose (Glu) were used to synthesize the FA-PEG-Chitosan-PCL-Chitosan-PEG-FA (FPCP) and Glu-PEG-Chitosan-PCL-Chitosan-PEG-Glu (GPCP) copolymers. Then, paclitaxel (PTX), oleic acid-coated FeCO nanoparticles (FeCO-OA) and 6-carboxy-fluorescein phosphoramidate (FAM)-labeled siRNA (siRNA-FAM) were encapsulated into either FPCP or GPCP, or both FPCP and GPCP (GFPCP), using the solvent evaporation technique. In vitro and in vivo biocompatibility and drug delivery efficiency of FPCP/FeCO-OA/PTX, GPCP/FeCO-OA/PTX and GFPCP/FeCO-OA/PTX nanoparticles were determined by recording the MTT assay, weight loss and tumor volume respectively. In addition, the ability of FPCP/FeCO-OA/siRNA-FAM, GPCP/FeCO-OA/siRNA-FAM, and GFPCP/FeCO-OA/siRNA-FAM gene transfer was determined using flow cytometry analysis. Moreover, the effects of applying an external magnetic field to the tumor site on the efficiency of drug delivery using FPCP/FeCO-OA/siRNA-FAM/PTX (NPsA), GPCP/FeCO-OA/siRNA-FAM/PTX (NPsB) and GFPCP/FeCO-OA/siRNA-FAM/PTX (NPsAB) were also investigated in the present study. No significant toxicity was observed for the FPCP and GPCP copolymers. Meanwhile, PTX encapsulated FPCP, GPCP and GFPCP exhibited greater anticancer activities against MCF-7 cells. The in vivo and in vitro results showed that the nanoparticles targeted with both folic acid and glucose increased drug and RNA transfer efficiency compared to when folic acid or glucose alone used. Also, the efficiency of PTX and siRNA-FAM delivery to tumor tissues by nanoparticles increased significantly by applying an external magnetic field to the tumor area. The hydrophobic interactions between different amphipathic copolymers in appropriate is an efficient and easy technique to synthesize complex and multifunctional nanoparticles.
Asunto(s)
Antineoplásicos , Neoplasias de la Mama , Nanopartículas , Ácidos Nucleicos , Preparaciones Farmacéuticas , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/genética , Línea Celular Tumoral , Portadores de Fármacos , Sistemas de Liberación de Medicamentos , Ácido Fólico , Humanos , Paclitaxel/farmacología , PolietilenglicolesRESUMEN
Metabolic syndrome (MetS) is characterized by a cluster of cardiovascular risk factors that include: abdominal obesity, dyslipidaemia, hypertension, insulin resistance and impaired glucose tolerance. Recent genome wide association studies have identified several susceptibility regions involved in lipid metabolism that are also associated with MetS. We have explored the association of 9 genetic polymorphisms involved in lipid metabolism and hypertension, including: MTHFR C677T, SELE L554F, FGB - 455G>A, GNB3 C825T, ZNF259 C>G, PSRC-1 A>G, CETP I405V, LPL S447X and LPA C>T in 97 subjects with MetS and 96 individuals without MetS who were recruited randomly from Mashhad stroke and heart atherosclerotic disorder (MASHAD) study using a stratified cluster random sampling technique. Anthropometric parameters and biochemical measurements were determined in all the subjects. Genotyping was carried out followed by univariate and multivariate analyses. The subjects with MetS had a higher triglyceride and lower HDL- C. CG+ GG genotypes of ZNF259 polymorphism (rs964184 C>G) and TT+CT genotypes of MTHFR C677T (rs1801133) were associated with MetS, and individuals carrying the G allele for ZNF259 or the T allele for MTHFR polymorphisms were associated with MetS (e.g, odds ratio (OR) for CG+GG genotypes vs. CC wild type: 2.52, CI=1.33-4.77; P=0.005). However, after multiple comparison adjustment, this relationship remained significant only for CG+ GG genotypes of ZNF259 polymorphism. Moreover, the ZNF259 CG+ GG genotypes were associated with increased serum concentrations of triglycerides and LDL-C, compared to the wild type. These data support the necessity for further studies in larger multicenter settings.